Cardiovascular Research Advance Access [Accepted Manuscript] published online on April 4, 2008
Cardiovascular Research, doi:10.1093/cvr/cvn086
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loss of Ischemic Preconditioning in Ovariectomized Rat Hearts: Possible Involvement of Impaired PKC
Phosphorylation
1 Department of Internal Medicine, Keio University School of Medicine, Tokyo, JAPAN
2 The Institute of Molecular Cardiology, University of Louisville, Louisville, KY, USA
Address for correspondence: Ken Shinmura, MD, PhD Department of Internal Medicine, Keio University School of Medicine 35 Shinanomachi, Shinjuku-ku Tokyo, JAPAN 160-8582 Telephone: +81-(3)-3353-1211 Ext. 62915 Fax: +81-(3)-5269-2468 E-mail: shimmura{at}sc.itc.keio.ac.jp
AIMS: The aims of this study were to determine whether chronic estrogen withdrawal influences the development of ischemic preconditioning (IPC) in female hearts, to investigate the mechanism whereby IPC is impaired, and to assess whether direct activation of protein kinase C (PKC) can mimic IPC in female hearts with chronic estrogen depletion.
METHODS: We performed sham-operation (Sham) or bilateral ovariectomy on 16-week-old Sprague-Dawley female rats. Ovariectomized rats were randomized to subcutaneous implantation of 17β-estradiol (OxE) or placebo (OxP) pellets. Four weeks later, isolated, perfused hearts were subjected to 30 min of ischemia followed by 120 min of reperfusion with or without 3 cycles of 5 min ischemia/5 min reperfusion.
RESULTS: The cardioprotective effect of IPC was completely lost in the OxP group. Western immunoblots revealed that in the OxP group, IPC failed to translocate PKC
to the membranous fraction and that phosphorylation of PKC
(Ser729) and of phosphoinositide-dependent kinase (PDK)1 (Ser241) was impaired. Estrogen replacement restored the IPC effect, the translocation and phosphorylation of PKC
, and the phosphorylation of PDK1. In the OxP group, pretreatment with a PKC
selective activator peptide (
-
RACK) mimicked the IPC effect. Pretreatment with a phosphatidylinositol-3 kinase inhibitor before IPC abrogated the translocation and phosphorylation of PKC
in the Sham group.
CONCLUSIONS: The cardioprotective effect of IPC is lost in female hearts with chronic estrogen withdrawal, and this is due, at least in part, to impaired translocation and phosphorylation of PKC
. Selective activation of PKC
-mediated signaling can fully restore the IPC effect, in a manner analogous to estrogen replacement.
Time for primary review: 28 days
Related Article
![]()
CiteULike
Connotea
Del.icio.us What's this?
Cardiovasc Res 2008 79: 353-354.
This article has been cited by other articles:
![]() |
M. V. Cohen and J. M. Downey Oestrogen plays a permissive role in cardioprotection Cardiovasc Res, August 1, 2008; 79(3): 353 - 354. [Full Text] [PDF] |
||||
